INTRODUCTION
Colorectal cancer is the third most common malignancy and the second leading cause of cancer-related death worldwide. 1 Twenty five percent of patients with colorectal cancer present with stage IV disease involving the liver at the time of diagnosis and an additional 50% will develop metachronous colorectal liver metastases (CRLM). 2 For patients with CRLM, resection is the only curative option but 80% of these patients present with unresectable disease. 3 Moreover, only 17-25% of patients are free of disease 10 years after resection. 4, 5 Current systemic chemotherapy offers a median survival time of only 20-24 months. 6 Novel therapeutic options are needed and immunotherapy is a promising alternative.
We recently completed the phase I Hepatic Immunotherapy for Metastases (HITM, NCT01373047) trial evaluating the safety and tolerability of anti-CEA chimeric antigen receptor-modified T cells (CAR-T). CAR-Ts are autologous lymphocytes engineered to target tumor antigens and have shown significant promise in recent years. 7, 8 We delivered CAR-T specific for carcinoembryonic antigen (CEA) by hepatic artery infusion (HAI) as we speculate that offtarget toxicity from systemic infusion of immunotherapeutics can be minimized through the use of regional delivery strategies. 9 Systems to define tumor response based on cross-sectional imaging lesion size changes, such as the response criteria in solid tumors (RECIST), were created primarily for cytotoxic chemotherapy studies. 10 Criteria based on changes in tumor size inadequately measure early tumor response after immunotherapy, as lesions may initially get larger because of inflammation and edema, in addition to response kinetics being prolonged in some cases. 11 As such, we are interested in studying alternative biological surrogates of early response to immunotherapy. We performed correlative work on HITM patient biospecimens to identify potential surrogates of early response to CAR-T HAI, as conventional imaging may not accurately characterize intrahepatic tumor response. 11 We examined serum cytokine changes following CAR-T HAI to determine if peripheral fluctuations in markers of inflammation correlated with immune activity in the liver. Interleukin 6 (IL6) is an inflammatory cytokine that has been linked to disease status, [12] [13] [14] tumor size 15 and presence of liver metastases (LM). 16 Colorectal cancer cells produce IL6 and increased IL6 levels correlate with progression and recurrence. 12 A decrease in serum IL6 levels following CRLM ablation or resection correlates with lower recurrence rates. 17, 18 IL6 has also been associated with the generation of proinflammatory IL17-producing CD4 T cells, or Th17 cells. 19 Serum levels of IL6 and IL17 not only serve as surrogates of tumor response, 20 but these cytokines also drive mobilization of neutrophils from the bone marrow, another correlate of outcome in solid tumor patients. 21, 22 The neutrophil:lymphocyte ratio (NLR) has been used as an indicator of immunity and inflammation in the tumor microenvironment. [23] [24] [25] High NLR has been linked to tumor immune evasion in the liver. 26 Several groups have reported an association between high NLR and poor outcomes in patients with CRLM. 21, 27 NLR, which is in part governed by IL6 and IL17 concentrations in the serum, could serve as an early marker of the inflammatory response within the intrahepatic space following CAR-T HAI. The goal of our study was to determine whether NLR and serum cytokine variations occurred following anti-CEA CAR-T HAI. Furthermore, we wished to assess if these variations in serum cytokines and NLR levels may reflect the anti-tumor activity of CAR-T within the intrahepatic space.
MATERIALS AND METHODS

Patients and clinical intervention
The six patients who completed the phase I HITM (NCT01373047) clinical trial were the subjects of our study. Eligibility criteria included documented CEA+ LM, elevated serum CEA levels, life expectancy greater than 4 months, adequate organ function and presence of unresectable disease progressive on standard systemic chemotherapy. The three patients in cohort 1 were treated with three anti-CEA CAR-T HAI doses in escalation manner (1 × 10 8 , 1 × 10 9 and 1 × 10 10 cells) without IL2 (IL2 − ). For cohort 2, the three patients received three HAI CAR-T doses at the maximum tolerated level (1 × 10 10 cells) in addition to continuous systemic IL2 (IL2+) infusion at 75 000 IU kg − 1 day − 1 via an ambulatory infusion pump. CAR-T doses were given 2 weeks apart and IL2 was administered from the time of the first dose until 2 weeks following the final CAR-T HAI. All patients received a small amount of IL2 (approximately 6 × 10 5 IU) with each CAR-T infusion, as IL2 was present in all cell preparations. All clinical doses of CAR-Ts were prepared at the Roger Williams Medical Center Cancer Immunotherapy GMP facility. HAI were delivered percutaneously via a femoral arterial approach in the Roger Williams Medical Center Interventional Radiology Suite.
Cytokines and neutrophil lymphocyte ratios
We measured serum levels of IL6 and IL17, in addition to peripheral blood NLR, in all patients at day 0 or baseline and days 1, 2, 4 and 7 after each CAR-T HAI, which were given at 2-week intervals. NLR and cytokines were measured up to 7 days following the final CAR-T infusion, with the exception of patient 4, who had no samples taken 1 day after his final infusion because of disease progression. ELISA (eBioscience, San Diego, CA, USA) was used to measure cytokines IL6 and IL17 concentration in serum. We calculated NLR from the absolute values of neutrophils and lymphocytes measured in complete blood count performed at the same time points. Fold changes were determined using the baseline sample and the final sample taken following the CAR-T HAI. Comparing pre-treatment levels to the final level in cohort 1 or the final level before IL2 discontinuation or dose reduction in cohort 2 determined CEA responses. 28 
Statistical analysis
Prism from GraphPad Software Inc. (La Jolla, CA, USA) was used for statistical analysis, Spearman test was used for receiver operating characteristics curves. A two-tailed t-test was used to compare means. A P value of ⩽ 0.05 was considered statistically significant. The NLR median for all patients was 8.6 and we chose 10 as the cutoff value to classify NLR as high or low for simplicity and ease of clinical use. For analyses stratified by CEA response, a positive response was considered to be at least a 10% decrease from baseline CEA level. 
RESULTS
Patient characteristics
Eight patients were enrolled in the phase I HITM trial, of which six received three hepatic artery anti-CEA CAR-T doses and were eligible for this study. The average age was 57 years old (range 51-66), and two patients were females and four were males (Table 1 ). Five patients had been diagnosed with unresectable CEA + CRLM and one with CEA+ ampullary adenocarcinoma. The first three patients received anti-CEA CAR-T HAI as an intrapatient escalation dose of 1 × 10 8 , 1 × 10 9 and 1 × 10 10 cells. The second cohort received three HAI at the 1 × 10 10 dose level with systemic IL2 infusions. Details pertaining to adverse events and response data are reported elsewhere. 28 NLRs following hepatic artery CAR-T infusions The mean NLR for the HITM trial patients ranged between 4.8 and 38.1 (Table 1 ). Patients 4, 7 and 8 had a mean NLR410, while patients 1, 5 and 6 had mean NLR ratioso10. Each patient demonstrated an increase in NLR at some point in response to CAR-T infusion when comparing baseline to peak values (Figure 1a ). We analyzed NLR fold change among patients treated with or without systemic IL2 to determine if cytokine support impacted this parameter. The mean NLR fold change was 1.39 for cohort 1 (− IL2) and 1.36 for cohort 2 (+IL2) (P = 0.48). However, the only two NLR decreases seen were in the +IL2 group (Figure 1b) . Importantly, these patients also demonstrated responses in terms of decreased serum CEA and increased fibrosis or necrosis in tumor biopsy specimens (not shown). 28 Serum IL6 and IL17 changes following hepatic artery CAR-T infusions We measured serum IL6 and IL17 levels at baseline (day 0) and then at days 1, 2, 4 and 7 following each CAR-T HAI which were given three times every 2 weeks. The mean IL6 fold change for all patients was 3.0 (range 1.2-6.6) ( Table 1) . Patients who received IL2 had the highest peak serum IL6 concentrations in response to CAR-T HAI, with levels of 287.9 and 200.3 pg ml −1 for patients 7 and 8, respectively (Figure 2a ). No significant differences in IL6 fold change was seen in the group of patients receiving IL2 during the CAR-T HAI compared with the group not receiving IL2 (P = 0.19). However, the highest IL6 mean fold change of 6.6 occurred with patient 7, who did receive IL2 (Figure 2b ). IL6 levels increased in all patients at variable time points after the administration of CAR-T HAI (Figure 2c ). We observed greater variability in post-infusion IL17 serum levels compared with that of IL6. The highest peak (1289.2 pg ml − 1 ) and average (1134.7 pg ml − 1 ) IL17 levels were found in patient 4 who did not receive IL2 and who progressed rapidly following his final CAR-T infusion (Figures 2d and e ). Patient 7 had IL17 detectable at only one time point while patient 8 had no detectable serum IL17. Patients 1 and 4 experienced decreased IL17 levels following CAR-T HAI while IL17 levels increased for patients 5 (+3.9 pg ml − 1 ) and 6 (+413.0 pg ml − 1 ). Having determined that both IL6 or IL17 levels increased at various time points in all patients following HAI of CAR-T, we compared cytokine and NLR changes for each patient given the role of IL6 and IL17 in the regulation of peripheral neutrophil dynamics.
Correlation of serum IL6 and IL17 levels with NLR variations after hepatic artery CAR-T infusions
Serum IL6 concentrations and NLR variations trended toward a positive correlation (r = 0.77, P = 0.10, Figure 3a ). The correlation between serum IL17 and NLR variations was weak (r = 0.2, P = 1.0, Figure 3b ). Following stratification of patients based on their mean NLR values, we found a trend towards higher mean serum IL6 concentrations in patients with higher mean NLR (P = 0.07, Figure 3c ). We did not find a similar trend when comparing IL17 levels between those who did or did not receive systemic IL2 support (not shown).
NLR correlates with serologic response after hepatic CAR-T infusions
To assess the correlation of NLR variations and anti-tumor activity of CAR-T HAI, CEA level was used as a surrogate of tumor response. We found a trend towards a correlation between NLR variations and CEA decreases (r = 0.71, P = 0.11) (Figure 4a) . We also performed a stratified analysis to compare NLR fold change in patients with or without favorable CEA responses to CAR-T infusion. A 10% decrease in the absolute value of CEA serum levels was considered a favorable response. We found that patients who had a favorable CEA response to CAR-T HAI were significantly more likely to have had lower NLR fold changes (P = 0.048, Figure 4b ).
DISCUSSION
We have demonstrated an increase in both serum IL6 and IL17 concentrations in patients with CEA+ LM following CAR-T HAI, accompanied by variations in NLR. To our knowledge, this is the first report to examine systemic inflammatory changes following regional hepatic infusion of a cellular immunotherapeutic product in patients with LM. Although our data are limited by the small number of patients in the phase I HITM trial, the findings presented herein provide evidence that HAI of CAR-T induced an inflammatory response within the intrahepatic space and beyond. Decreases in NLR correlated with CEA responses to treatment. As such, increases in NLR levels after CAR-T HAI may predict lack of response to CAR-T HAI.
Recently, several biomarkers have been studied as surrogates of inflammatory responses that favor tumor progression. The most commonly used have been C-reactive protein, absolute or static NLR and platelet-lymphocyte ratio. High levels of these biological markers have been associated with poor prognosis in colorectal, gastro-esophageal and renal cell cancers. 24 A NLR of 5 or more has Immunotherapy for liver metastases been significantly associated with poor prognosis in metastatic colorectal adenocarcinoma. 23 Several studies have focused on NLR and its role as a prognostic factor in patients undergoing locoregional therapy for various solid tumors, including CRLM. 25, 29, 30 To our knowledge, this is the first publication examining NLR variations from baseline following treatment with genetically modified T cells. High levels of IL6 and IL17 promote NLR increases and have been associated with an immunosuppressive inflammatory state. 19 NLR might not only play a role as a prognostic marker as shown in prior studies, but as a surrogate of response in patients receiving immunotherapy. Patients with high NLR fold changes exhibited poor CEA responses. The correlation between NLR variations and CEA levels after CAR-T HAI suggest that NLR variations may be useful as a surrogate marker of tumor response.
It is not clear if IL2 had direct effects on IL6, NLR and CEA levels, or if IL2 promoted a more robust anti-tumor immune response by CAR-T with subsequent decrease of NLR and CEA levels. 31 IL2 is known to promote the expansion of peripheral lymphocyte populations, and as such may have expanded peripheral lymphocytes and hence lowered the NLR in cohort 2. Systemic cytokine and NLR responses were seen both in subjects who did and did not receive systemic IL2 support. The highest IL6 responses were seen in cohort 2, but IL17 fluctuations did not seem to relate to IL2 infusion. This suggests that IL2 contributes to the systemic cytokine response to CAR-T HAI, but the response is not dependent on IL2. Interestingly, NLR fold changes in cohort 2 were negative in two of three patients (−1.3 and − 5.8). We cannot determine if the IL2 effects noted in this study were a consequence of enhanced CAR-T activity within the liver or were peripheral effects of IL2 independent of CAR-T function. We speculate that following CAR-T HAI, NLR is not only dependent on IL6 and IL17, but is positively impacted by both IL2 infusion and the effect of IL2 on CAR-T function. Lower NLR may also be indicative of a more favorable immunologic context within the intrahepatic space, thereby promoting CAR-T anti-tumor activity independent of IL2 infusions.
The use of NLR variations to assess early immunotherapy responses adds to the existing literature that has established the role of static NLR as a prognostic factor in patients with CRLM. 21, 26, 27, 32 Our data must be interpreted within the context of the study design limitations. The primary objective of the HITM trial was to evaluate the safety of CAR-T HAI, and so it was not powered to draw conclusions about the use of cytokines or NLR as predictors of long-term outcome. Our data suggest a role for NLR variation as a predictor of response to CAR-T HAI but not as a prognostic factor. We studied a small number of patients with unresectable CRLM, which may limit our ability to draw conclusions and allow us to identify only large differences with very small standard deviations. Additionally, our patients presented with advanced disease following heavy pre-treatment with cytotoxic therapy. 28 Further work is required to determine the utility of NLR and inflammatory cytokine measurements following CAR-T HAI in patients with lower disease burdens.
Immunotherapy has evolved considerably in the last decade and is becoming an integral component of the multidisciplinary management of solid organ tumors. Evaluation of tumor response after immunotherapy for solid organ tumors is challenging, as the classic RECIST criteria are not reliable indicators in this setting. 11 We have shown that an increase in NLR after treatment correlates with increased CEA levels, a classic serological marker of CRLM progression. 33 Our findings suggest that systemic variations of NLR and inflammatory cytokines can reflect the response to CAR-T activity within the intrahepatic space. Easily measured surrogates of immunologic or inflammatory activity such as NLR and serum cytokines deserve further study as indicators of immunotherapeutic agent activity. 
